Literature DB >> 12151764

Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease.

Mitchell K P Lai1, Shirley W Y Tsang, Paul T Francis, Janet Keene, Tony Hope, Margaret M Esiri, Ian Spence, Christopher P L-H Chen.   

Abstract

Serotonin1A receptor density and serotonin concentration were measured in the postmortem neocortex of 17 AD patients who had been prospectively assessed every four months with the Mini-Mental State Examination (MMSE) for a mean of 2.6 years till death. In the frontal cortex, serotonin levels correlated negatively with the annual rate of MMSE decline, while serotonin1A receptor density was positively correlated with the rate of MMSE decline. Our study suggests that reduced serotonin levels and increased serotonin1A receptor density are markers for accelerated cognitive decline in AD, and provides support for the use of serotonin1A antagonists in the treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151764     DOI: 10.1097/00001756-200207020-00021

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

1.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

Review 2.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Tsang; Margaret M Esiri; Paul T Francis; Peter T-H Wong; Christopher P Chen
Journal:  Psychopharmacology (Berl)       Date:  2010-07-13       Impact factor: 4.530

Review 4.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

5.  Constitutive and Acquired Serotonin Deficiency Alters Memory and Hippocampal Synaptic Plasticity.

Authors:  Sebastian P Fernandez; Aude Muzerelle; Sophie Scotto-Lomassese; Jacques Barik; Agnès Gruart; José M Delgado-García; Patricia Gaspar
Journal:  Neuropsychopharmacology       Date:  2016-07-27       Impact factor: 7.853

6.  Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.

Authors:  M K Lai; S W Tsang; J T Alder; J Keene; T Hope; M M Esiri; P T Francis; C P Chen
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

Review 7.  A pharmacological analysis of an associative learning task: 5-HT(1) to 5-HT(7) receptor subtypes function on a pavlovian/instrumental autoshaped memory.

Authors:  Alfredo Meneses
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

8.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

9.  Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.

Authors:  S W Y Tsang; P T Francis; M M Esiri; P T H Wong; C P L H Chen; M K P Lai
Journal:  Psychopharmacology (Berl)       Date:  2008-03-30       Impact factor: 4.530

10.  Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease.

Authors:  Soumya Mukherjee; Manas Seal; Somdatta Ghosh Dey
Journal:  J Biol Inorg Chem       Date:  2014-09-24       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.